These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 18260185

  • 1. Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).
    Yaman E, Benekli M, Coskun U, Ozturk B, Kaya AO, Yildiz R, Buyukberber S.
    Ann Oncol; 2008 Feb; 19(2):397-8; author reply 398. PubMed ID: 18260185
    [No Abstract] [Full Text] [Related]

  • 2. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [Abstract] [Full Text] [Related]

  • 3. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
    Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N.
    Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
    [Abstract] [Full Text] [Related]

  • 4. Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
    Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris AL, Bottini A, Dogliotti L, Angeli A, Berruti A.
    Br J Cancer; 2008 Jun 03; 98(11):1753-8. PubMed ID: 18506177
    [Abstract] [Full Text] [Related]

  • 5. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
    Macpherson IR, Bray C, Hopkins C, Hannon RA, Lewsley LA, Ritchie DM, Canney P.
    Clin Breast Cancer; 2015 Apr 03; 15(2):117-27. PubMed ID: 25454689
    [Abstract] [Full Text] [Related]

  • 6. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
    Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, Migali C, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R.
    Int J Clin Oncol; 2011 Jun 03; 16(3):264-9. PubMed ID: 21240683
    [Abstract] [Full Text] [Related]

  • 7. Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer.
    Wang R, Zhang S, Jiang Z, Tian J, Wang T, Song S.
    Clin Exp Pharmacol Physiol; 2017 Jan 03; 44(1):88-93. PubMed ID: 27716993
    [Abstract] [Full Text] [Related]

  • 8. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
    Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, Jung K.
    Eur Urol; 2007 Nov 03; 52(5):1381-7. PubMed ID: 17321667
    [Abstract] [Full Text] [Related]

  • 9. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, Shao Z, Zhu J, Guo X, Chen J, Zhu B, Wang Z, Hu X.
    Breast Cancer Res Treat; 2010 Dec 03; 124(3):733-43. PubMed ID: 20882405
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Support Care Cancer; 2005 Dec 03; 13(12):975-86. PubMed ID: 15871033
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Clin Ther; 2005 Aug 03; 27(8):1295-310. PubMed ID: 16199254
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ.
    Cancer; 2001 Apr 01; 91(7):1191-200. PubMed ID: 11283917
    [Abstract] [Full Text] [Related]

  • 13. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
    Mishra A.
    J Postgrad Med; 2008 Apr 01; 54(3):237. PubMed ID: 18626181
    [No Abstract] [Full Text] [Related]

  • 14. [Zoledronic acid and bone pathology in the course of neoplasia. Part I].
    Caffo O.
    Tumori; 2005 Apr 01; 91(5):22-6. PubMed ID: 16459649
    [No Abstract] [Full Text] [Related]

  • 15. Bisphosphonates in breast cancer.
    Coleman RE.
    Ann Oncol; 2005 May 01; 16(5):687-95. PubMed ID: 15802276
    [Abstract] [Full Text] [Related]

  • 16. Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid.
    Jung K, Miller K, Wirth M, Albrecht M, Lein M.
    Eur Urol; 2011 Apr 01; 59(4):604-12. PubMed ID: 21190792
    [Abstract] [Full Text] [Related]

  • 17. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
    Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN.
    J Natl Cancer Inst; 2020 Jul 01; 112(7):698-707. PubMed ID: 31693129
    [Abstract] [Full Text] [Related]

  • 18. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.
    Cameron D.
    Breast; 2003 Aug 01; 12 Suppl 2():S22-9. PubMed ID: 14659140
    [Abstract] [Full Text] [Related]

  • 19. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
    Nelson A, Fenlon D, Morris J, Sampson C, Harrop E, Murray N, Wheatley D, Hood K, Griffiths G, Barrett-Lee P.
    Trials; 2013 Oct 09; 14():325. PubMed ID: 24107437
    [Abstract] [Full Text] [Related]

  • 20. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Oct 09; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.